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I In nt tr ro od du uc ct ti io on n
IMPACT (Identification of Men with a genetic
predisposition to ProstAte Cancer: Targeted screening in
BRCA1/2 mutation carriers and controls) is an
international collaboration investigating the utility of
targeted prostate-specific antigen (PSA) screening for men
at increased risk of prostate cancer due to inherited
predisposition. Although the majority of prostate cancer
occurs sporadically, it is recognized that family history
plays a role in a significant number of cases: a family
history either of prostate cancer alone [1], or of other
cancers including breast and ovarian cancer [2]. Evidence
of the link between single genes and prostate cancer risk
is strongest for the BRCA1 and BRCA2 genes [3-5], with
BRCA2 in particular thought to lead to a relative risk of
4.65 (95%CI 3.48-6.22). This relative risk may be as
high as 7.33 in men under the age of 65 years.
Population prostate cancer screening remains
controversial because of the potential for detection of
clinically insignificant disease in young men and the risk
of over-treatment. There is increasing interest and
concern in European countries about whether prostate
cancer screening should be offered to the general
population and whether this would lead to a reduction
in mortality from prostate cancer. IMPACT raises the
hypothesis that targeting screening at the men in the
population who are known to have an increased risk of
the disease might improve the effectiveness of prostate
cancer screening. Beginning with a pilot of 100 patients,
the IMPACT study ultimately aims to recruit a total of 850
carriers of mutations in BRCA1 and BRCA2 and 850
controls (men shown not to carry familial BRCA1/2
mutations by predictive genetic testing). Recruitment will
be open for five years, followed by five years of follow-up.
In 2005, a project known as AIDIT (Advancing
International co-operation and Developing Infra-
structure for Targeted screening of prostate cancer in
men with genetic predisposition) was awarded funding
through the EC Framework 6 Programme as part of an
endeavour to reduce research fragmentation and
duplication, and to facilitate research collaboration
across Europe. IMPACT currently includes collaborators
from 24 countries. AIDIT’s aim is to expand the
IMPACT consortium within the associated candidate
countries (ACCs) and new member states of the EU.
The expansion of IMPACT is likely to benefit both the
study and the research teams: a higher number of
collaborating centres will allow access to a larger
number of men at risk, making it possible to recruit as
many carriers as are needed for the study, particularly
in populations likely to harbour founder mutations; and
for all collaborators – both new and existing – it is
hoped that participation in AIDIT and IMPACT will foster
an environment of ongoing interaction and learning. H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(1) 54
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T Th he e   A AI ID DI IT T   a an nd d   I IM MP PA AC CT T   c co on nf fe er re en nc ce e
To facilitate the international collaboration necessary
for a project such as IMPACT, the AIDIT project provided
funding for a conference, held from November 28
th to
30
th 2006 in Szczecin, Poland. Attended by 117
delegates from 30 countries, it provided a unique
opportunity to bring together researchers, clinicians and
other experts from across the world. In accordance with
AIDIT’s aim to welcome potential collaborators from
the ACCs, 20 delegates from a range of specialties in
Romania, Bulgaria and Turkey attended, as well as 
a representative of the National Cancer Research
Programme in Croatia, a country recently included as
an ACC. A total of 32 delegates from nine of the ten
new member states were also present. 
The meeting was officially opened by Professor
Przemyslaw Nowacki, Rector of Pomeranian Medical
University, with welcome addresses provided by Prof
Lubinski, conference host, and Dr Ros Eeles, Principal
Investigator of IMPACT.
P Pr ro og gr ra am mm me e
The conference programme included presentations
from world leaders in fields as diverse as cancer genetics,
urology, pathology, oncology and epidemiology. Abstracts
and speaker biographies can be found on the IMPACT
study website (www.impact-study.co.uk). 
Day 1 focused on the scientific rationale for
IMPACT, beginning with a summary from Dr Eeles of
the study’s background and aims. Subsequent
presentations provided an overview of the genetics of
inherited prostate cancer, including cancer risks in
carriers of BRCA1 and BRCA2 mutations (Prof Doug
Easton, UK), and a summary of other potential prostate
cancer susceptibility genes being investigated in Poland
(Prof Cezary Cybulski, Poland). 
The use of PSA as a screening tool for prostate
cancer stimulates debate across the world; several
presentations therefore focused on screening both in
the general population and in those with an inherited
risk. Results from the ERSPC and ProtecT population-
-based prostate screening studies, respectively, were
presented (Dr Monique Roobol, The Netherlands, and
Prof Freddie Hamdy, UK), and an insight provided into
the risks and benefits associated with both population
and targeted screening (Dr Jane Warwick, UK). Prof
Kari Hemminki (Germany) spoke about the effect of
PSA screening and changing prostate cancer incidence
on our understanding of familial prostate cancer risk.
The second day of the conference began with an
update of progress in those countries beginning to recruit
to IMPACT. In the UK, where 17 centres are participating,
51 of the 100 pilot patients had been recruited at the
time of the conference: 15 carriers of BRCA1, 22 of
BRCA2, and 14 controls. Using a cut-off of 3ng/ml, four
men have had raised PSA levels, with one carrier of 
a BRCA1 mutation having prostate cancer diagnosed
on biopsy. Norway has recruited 10 BRCA2 carriers, one
of whom is awaiting biopsy after a raised PSA. Australia,
Germany and Spain will begin recruitment in early 2007. 
Participation in IMPACT requires that patients have
undergone predictive genetic testing for the BRCA1 or
BRCA2 genes, but the infrastructure behind this testing,
both technical and clinical, varies across the world and,
at times, within countries. The rest of Day 2 therefore
focused on issues related to setting up and maintaining
this infrastructure. A clinical insight was provided by
Prof Gareth Evans (UK), who discussed the manage-
ment of individuals who carry mutations in BRCA1. Due
to injury, Prof Kathryn Kash (USA) was unfortunately
unable to present information on the ethical and
psychological implications of genetic testing, but she
was replaced by Prof Christopher Foster (UK), who
spoke of the interface between prostate cancer genetics
and pathology.
The current status of genetic testing across Europe
was summarized by Prof Gert Matthijs, Deputy
Coordinator of EuroGentest, a network for genetic test
development, harmonization, validation and standar-
dization. Perspectives were then provided from the UK,
The Netherlands and Poland with regard to developing
genetic testing services (Dr John Harvey, UK; Dr Jan
Oosterwijk, The Netherlands; Prof Jan Lubinski, Poland).
Prof Rodney Scott (Australia) broadened the discussion
by raising future considerations for genetic testing,
including improvements in technology and a better
understanding of the role of modifier genes.
I In nt te er rn na at ti io on na al l   c co ol ll la ab bo or ra at ti io on n
The final day of the conference was directed
towards the advancement of international collaboration
within IMPACT, with the main focus being the status of
genetics and prostate cancer screening services in the
ACCs. Discussion centred on funding, infrastructure,
government support, public awareness and the role of
clinicians and researchers in lobbying major
stakeholders. Reports were provided by Dr Esra
Manguoglu and Prof Guven Luleci (Turkey); Dr Vlad-
Alexandru Mixich and Prof Francisc Mixich (Romania);
and Prof Stoyan Lalchev, Prof Ivanka Dimova and Dr
Radka Kaneva (Bulgaria). Research teams in all of the
ACCs were enthusiastic about participation in IMPACT.
The conference facilitated new working relationships,
both within IMPACT and externally. Although the aim ofH He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2007; 5(1) 55
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the conference was to extend links with the ACCs and to
develop the IMPACT consortium, it also played an
important role in strengthening research ties in a range
of fields. A meeting of this nature and size provided 
a unique opportunity to bring together individuals with
similar research interests, but also allowed those with
diverse backgrounds to share opinions and experience.
New research projects were initiated, and existing projects
broadened.
F Fu ut tu ur re e   c co on ns si id de er ra at ti io on ns s
Following the conference, several new research teams
will be integrated into the IMPACT consortium. Although
not all will be able to begin active recruitment
immediately, the fact that the study is being run over
several years will allow time for development of
procedures and services. A network of international
experts can also share ideas about overcoming potential
barriers to participation in the study. Since the
conference, several teams have already begun to work
on the issue of funding for genetic testing, either pursuing
applications for research funding or approaching health
ministries for support.
Those teams who do begin to recruit will be
contributing to a growing resource which is likely to
contribute a wealth of information to the field of prostate
cancer genetics. It is hoped that IMPACT will not only
determine whether PSA is an appropriate screening tool
for men at high risk, but will identify potential new markers
of prostate cancer risk and expand knowledge about the
pathology of tumours in men carrying genes predisposing
to prostate cancer. Close international collaboration will
be fundamental to the achievement of these goals.
Further information about the IMPACT study can be
found on the website www.impact-study.co.uk and
expressions of interest are welcome.
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